Lecanemab for AD Shows Sustained Benefit in Real-World Study

https://www.medscape.com/viewarticle/lecanemab-ad-shows-sustained-benefit-real-world-study-2026a1000ofl?ecd=WNL_trdalrt_pos1_ous_260722_etid8527635&uac=148436CN&impID=8527635 LONDON — More than 80% of patients with early Alzheimer’s disease (AD) treated with lecanemab (Leqembi, Eisai/Biogen) in routine practice remained clinically stable or improved over an average of 17 months of treatment, an interim analysis of the real-world LEADER study showed.